Holmium laser enucleation of the prostate (HoLEP) has a well-established body of evidence demonstrating superior durability and reduced morbidity to other transurethral benign prostatic hyperplasia (BPH) surgeries, with some arguing that HoLEP should replace transurethral resection of the prostate (TURP) as the new gold standard. However, HoLEP has yet to gain widespread adoption in the United States. There are many possible reasons for this, perhaps most notably a steep learning curve.